Larimar Therapeutics, Inc. filed a Form 8-K on November 9, 2026, disclosing the completion of its rolling Biologics License Application submission to the U.S. Food and Drug Administration seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich's ataxia, and reporting a preliminary cash position as of September 30, 2026.

Key Highlights

  • BLA Submission Completed: Larimar Therapeutics completed its rolling BLA submission to the FDA seeking accelerated approval of nomlabofusp for Friedreich's ataxia, according to the filing.
  • Preliminary Cash Position: As of September 30, 2026, the company reported approximately $128.7 million of cash, cash equivalents, and marketable securities.
  • Unaudited and Preliminary Figure: The company disclosed that its quarter-end financial close for the quarter ended September 30, 2026 had not yet been completed and the cash figure is subject to change.
  • Exchange and Ticker: Larimar's common stock trades on the Nasdaq Global Market under NASDAQ:LRMR.
  • Updated Corporate Presentation: The company posted an updated slide presentation on its website on November 9, 2026, to be used in meetings with investors, analysts, and other parties.

Larimar Therapeutics Discloses BLA Completion and Preliminary Financials

According to the Form 8-K filed on November 9, 2026, Larimar Therapeutics, Inc. (NASDAQ:LRMR) announced in a press release that it completed its rolling Biologics License Application submission to the U.S. Food and Drug Administration. The BLA seeks accelerated approval of nomlabofusp for the treatment of patients with Friedreich's ataxia. The press release is attached as Exhibit 99.1 to the filing.

The filing also disclosed, through an updated slide presentation posted to the company's website, a preliminary cash figure. As of September 30, 2026, the company had approximately $128.7 million of cash, cash equivalents, and marketable securities, the filing stated. However, Larimar cautioned that "the Company has not yet completed its quarter-end financial close processes for the quarter ended September 30, 2026" and that "the review of the Company's financial statements for the quarter ended September 30, 2026 is ongoing and could result in changes to this amount." The company further noted the figure "is preliminary, has not been audited" and "does not present all information necessary for an understanding of the Company's financial condition."

The filing was signed by Carole S. Ben-Maimon, M.D., Chief Executive Officer of Larimar Therapeutics. The company also noted that the updated corporate presentation, attached as Exhibit 99.2, will be used by company representatives "in various meetings with investors, analysts and other parties from time to time." The financial data disclosed under Item 2.02 is designated as furnished, not filed, for purposes of the Securities Exchange Act of 1934.

What Was Disclosed

Larimar Therapeutics disclosed the completion of its rolling BLA submission to the FDA for nomlabofusp in Friedreich's ataxia and provided a preliminary, unaudited cash position of approximately $128.7 million as of September 30, 2026, subject to revision upon completion of financial close procedures.